Literature DB >> 9450231

Molecular pathogenesis of Theiler's murine encephalomyelitis virus-induced demyelinating disease in mice.

H L Lipton1, M L Jelachich.   

Abstract

After an acute phase of virus growth in neurons (e.g. anterior horn cells), Theiler's murine encephalomyelitis virus (TMEV) persists as a chronic productive infection, largely in macrophages in the CNS white matter. TMEV replication in macrophages is highly restricted, probably as the result of host cell factors. The preponderance of evidence indicates that TMEV persistence leads to immunopathologic damage of myelin, mediated by major histocompatibility class II-restricted Th1 lymphocytes directed at a virus epitope(s) rather than host neuroantigens at least early in the infection. Analysis of TMEV recombinant and mutant viruses suggests that persistence requires a specific capsid conformation involving the VP2 puff and VP1 loops, which may influence persistence through virion receptor binding or attachment to host cells, e.g. macrophages.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9450231     DOI: 10.1159/000150541

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  11 in total

1.  Distinct attenuation phenotypes caused by mutations in the translational starting window of Theiler's murine encephalomyelitis virus.

Authors:  E V Pilipenko; E G Viktorova; E V Khitrina; S V Maslova; N Jarousse; M Brahic; V I Agol
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  Infection of macrophage primary cultures by persistent and nonpersistent strains of Theiler's virus: role of capsid and noncapsid viral determinants.

Authors:  Ignacio Mena; Jean-Pierre Roussarie; Michel Brahic
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

3.  Different subcellular localization of Theiler's murine encephalomyelitis virus leader proteins of GDVII and DA strains in BHK-21 cells.

Authors:  Naoko Taniura; Mineki Saito; Takako Okuwa; Kousuke Saito; Yoshiro Ohara
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

4.  A central role for CD4(+) T cells and RANTES in virus-induced central nervous system inflammation and demyelination.

Authors:  T E Lane; M T Liu; B P Chen; V C Asensio; R M Samawi; A D Paoletti; I L Campbell; S L Kunkel; H S Fox; M J Buchmeier
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

5.  A critical role for virus-specific CD8(+) CTLs in protection from Theiler's virus-induced demyelination in disease-susceptible SJL mice.

Authors:  Meghann Teague Getts; Maureen H Richards; Stephen D Miller
Journal:  Virology       Date:  2010-04-08       Impact factor: 3.616

6.  Immune-mediated protection from measles virus-induced central nervous system disease is noncytolytic and gamma interferon dependent.

Authors:  Catherine E Patterson; Diane M P Lawrence; Lisa A Echols; Glenn F Rall
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

Review 7.  Theiler's murine encephalomyelitis virus infection of SJL/J and C57BL/6J mice: Models for multiple sclerosis and epilepsy.

Authors:  Ana Beatriz DePaula-Silva; Tyler J Hanak; Jane E Libbey; Robert S Fujinami
Journal:  J Neuroimmunol       Date:  2017-02-12       Impact factor: 3.478

8.  Central neuroinvasion and demyelination by inflammatory macrophages after peripheral virus infection is controlled by SHP-1.

Authors:  George P Christophi; Paul T Massa
Journal:  Viral Immunol       Date:  2009-12       Impact factor: 2.257

9.  Modulation of macrophage infiltration and inflammatory activity by the phosphatase SHP-1 in virus-induced demyelinating disease.

Authors:  George P Christophi; Chad A Hudson; Michael Panos; Ross C Gruber; Paul T Massa
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

Review 10.  Theiler's virus infection: a model for multiple sclerosis.

Authors:  Emilia L Oleszak; J Robert Chang; Herman Friedman; Christos D Katsetos; Chris D Platsoucas
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.